argenx SE (ARGX) Q4 2025 Earnings Call Transcript
Source: SeekingAlpha
2026-02-26 12:57:59 ET
argenx SE (ARGX) Q4 2025 Earnings Call February 26, 2026 8:30 AM EST
Company Participants
Beth DelGiacco - VP and Global Head of Corporate Communications & Investor Relations
Karen Massey - Chief Operating Officer
Luc Truyen - Chief Medical Officer
Karl Gubitz - Chief Financial Officer
Sandrine Piret-Gerard
Tim Van Hauwermeiren - Co-Founder, CEO & Executive Director
...
Read the full article on Seeking Alpha
For further details see:
argenx SE (ARGX) Q4 2025 Earnings Call Transcript
Argen X SE
NASDAQ: ARGNF
ARGNF Trading
2.56% G/L:
$814.94 Last:
2 Volume:
$814.94 Open:
ARGNF Latest News
March 06, 2026 01:00:00 am
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
February 26, 2026 01:00:00 am
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
February 26, 2026 12:30:00 am
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
ARGNF Stock Data
$50,515,067,402
49,738,024
N/A
478
N/A
Biotechnology & Life Sciences
Healthcare
NL
Amsterdam
